Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 2/2016

01.02.2016 | Original Article – Clinical Oncology

Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins

verfasst von: Tanja Ignatov, Holm Eggemann, Elke Burger, Serban Dan Costa, Atanas Ignatov

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The survival effect of adjuvant radiotherapy (RT) for vulvar cancer has been poorly investigated.

Patients and methods

We performed a multicentre retrospective register study of 257 patients with primary squamous vulvar cancer. The survival effect of adjuvant RT was investigated in two groups of patients, dependent on surgical margins. The outcome measure was overall survival. All statistical tests were two-sided.

Results

Of the 257 patients investigated, 192 had negative resection margins, while positive and/or close surgical margins were observed in 65 cases. Margin status was associated with unfavourable overall survival. The five-year overall survival was 66.1 and 49.2 % in patients with negative and positive/close resection margins, respectively. Adjuvant RT directed to the vulva was associated with improved survival in patients with positive/close resection margins but not in patients with negative surgical margins. The 5-year overall survival of patients with positive/close surgical margins without RT was 29 %, whereas with RT it increased to 67.6 %. Notably, patients with positive/close surgical margins who received RT of the vulva had a 5-year survival rate similar to the patients with negative margins (67.6 %). Multivariate analysis adjusted for age, stage of disease, tumour grade and lymph node metastases showed that adjuvant RT significantly reduced the mortality risk in patients with positive/close resection margins (HR 0.36, CI 0.14–0.94, p = 0.038). In the group of patients with negative resection margins, the involvement of lymph nodes was the strongest unfavourable prognostic factor.

Conclusions

Adjuvant RT should be used for patients with positive/close surgical margins to improve their outcome.
Literatur
Zurück zum Zitat Busch M, Wagener B, Schaffer M, Duhmke E (2000) Long-term impact of postoperative radiotherapy in carcinoma of the vulva FIGO I/II. Int J Radiat Oncol Biol Phys 48:213–218PubMedCrossRef Busch M, Wagener B, Schaffer M, Duhmke E (2000) Long-term impact of postoperative radiotherapy in carcinoma of the vulva FIGO I/II. Int J Radiat Oncol Biol Phys 48:213–218PubMedCrossRef
Zurück zum Zitat Chan JK, Sugiyama V, Pham H, Gu M, Rutgers J, Osann K, Cheung MK, Berman ML, Disaia PJ (2007) Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 104:636–641PubMedCrossRef Chan JK, Sugiyama V, Pham H, Gu M, Rutgers J, Osann K, Cheung MK, Berman ML, Disaia PJ (2007) Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 104:636–641PubMedCrossRef
Zurück zum Zitat de Hullu JA, van der Zee AG (2006) Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol 60:38–58PubMedCrossRef de Hullu JA, van der Zee AG (2006) Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol 60:38–58PubMedCrossRef
Zurück zum Zitat Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F, Thomssen C, Costa SD, Ignatov A (2015) Moderate HER2 expression as prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer 22:725–733PubMedCrossRef Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F, Thomssen C, Costa SD, Ignatov A (2015) Moderate HER2 expression as prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer 22:725–733PubMedCrossRef
Zurück zum Zitat Faul CM, Mirmow D, Huang Q, Gerszten K, Day R, Jones MW (1997) Adjuvant radiation for vulvar carcinoma: improved local control. Int J Radiat Oncol Biol Phys 38:381–389PubMedCrossRef Faul CM, Mirmow D, Huang Q, Gerszten K, Day R, Jones MW (1997) Adjuvant radiation for vulvar carcinoma: improved local control. Int J Radiat Oncol Biol Phys 38:381–389PubMedCrossRef
Zurück zum Zitat Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR (2006) Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol 60:227–241PubMedCrossRef Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR (2006) Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol 60:227–241PubMedCrossRef
Zurück zum Zitat Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS (1990) Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 38:309–314PubMedCrossRef Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS (1990) Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 38:309–314PubMedCrossRef
Zurück zum Zitat Ignatov T, Eggemann H, Burger E, Fettke F, Costa SD, Ignatov A (2015) Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. Breast Cancer Res Treat 151:357–364PubMedCrossRef Ignatov T, Eggemann H, Burger E, Fettke F, Costa SD, Ignatov A (2015) Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. Breast Cancer Res Treat 151:357–364PubMedCrossRef
Zurück zum Zitat Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA (2006) Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 107:1018–1022PubMedCrossRef Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA (2006) Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 107:1018–1022PubMedCrossRef
Zurück zum Zitat Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L (2015) Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 107:dju426PubMedPubMedCentralCrossRef Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L (2015) Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 107:dju426PubMedPubMedCentralCrossRef
Zurück zum Zitat Pao WM, Perez CA, Kuske RR, Sommers GM, Camel HM, Galakatos AE (1988) Radiation therapy and conservation surgery for primary and recurrent carcinoma of the vulva: report of 40 patients and a review of the literature. Int J Radiat Oncol Biol Phys 14:1123–1132PubMedCrossRef Pao WM, Perez CA, Kuske RR, Sommers GM, Camel HM, Galakatos AE (1988) Radiation therapy and conservation surgery for primary and recurrent carcinoma of the vulva: report of 40 patients and a review of the literature. Int J Radiat Oncol Biol Phys 14:1123–1132PubMedCrossRef
Zurück zum Zitat Perez CA, Grigsby PW, Chao C, Galakatos A, Garipagaoglu M, Mutch D, Lockett MA (1998) Irradiation in carcinoma of the vulva: factors affecting outcome. Int J Radiat Oncol Biol Phys 42:335–344PubMedCrossRef Perez CA, Grigsby PW, Chao C, Galakatos A, Garipagaoglu M, Mutch D, Lockett MA (1998) Irradiation in carcinoma of the vulva: factors affecting outcome. Int J Radiat Oncol Biol Phys 42:335–344PubMedCrossRef
Zurück zum Zitat Piura B, Masotina A, Murdoch J, Lopes A, Morgan P, Monaghan J (1993) Recurrent squamous cell carcinoma of the vulva: a study of 73 cases. Gynecol Oncol 48:189–195PubMedCrossRef Piura B, Masotina A, Murdoch J, Lopes A, Morgan P, Monaghan J (1993) Recurrent squamous cell carcinoma of the vulva: a study of 73 cases. Gynecol Oncol 48:189–195PubMedCrossRef
Zurück zum Zitat Rouzier R, Haddad B, Plantier F, Dubois P, Pelisse M, Paniel BJ (2002) Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol 100:1159–1167PubMedCrossRef Rouzier R, Haddad B, Plantier F, Dubois P, Pelisse M, Paniel BJ (2002) Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol 100:1159–1167PubMedCrossRef
Zurück zum Zitat Rouzier R, Haddad B, Atallah D, Dubois P, Paniel BJ (2005) Surgery for vulvar cancer. Clin Obstet Gynecol 48:869–878PubMedCrossRef Rouzier R, Haddad B, Atallah D, Dubois P, Paniel BJ (2005) Surgery for vulvar cancer. Clin Obstet Gynecol 48:869–878PubMedCrossRef
Zurück zum Zitat Viswanathan AN, Pinto AP, Schultz D, Berkowitz R, Crum CP (2013) Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma. Gynecol Oncol 130:545–549PubMedCrossRef Viswanathan AN, Pinto AP, Schultz D, Berkowitz R, Crum CP (2013) Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma. Gynecol Oncol 130:545–549PubMedCrossRef
Zurück zum Zitat von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457CrossRef von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457CrossRef
Zurück zum Zitat Woelber L, Choschzick M, Eulenburg C, Hager M, Jaenicke F, Gieseking F, Kock L, Ihnen M, Petersen C, Schwarz J, Mahner S (2011) Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva. Ann Surg Oncol 18:3811–3818PubMedCrossRef Woelber L, Choschzick M, Eulenburg C, Hager M, Jaenicke F, Gieseking F, Kock L, Ihnen M, Petersen C, Schwarz J, Mahner S (2011) Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva. Ann Surg Oncol 18:3811–3818PubMedCrossRef
Zurück zum Zitat Woelber L, Trillsch F, Kock L, Grimm D, Petersen C, Choschzick M, Jaenicke F, Mahner S (2013) Management of patients with vulvar cancer: a perspective review according to tumour stage. Ther Adv Med Oncol 5:183–192PubMedPubMedCentralCrossRef Woelber L, Trillsch F, Kock L, Grimm D, Petersen C, Choschzick M, Jaenicke F, Mahner S (2013) Management of patients with vulvar cancer: a perspective review according to tumour stage. Ther Adv Med Oncol 5:183–192PubMedPubMedCentralCrossRef
Metadaten
Titel
Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins
verfasst von
Tanja Ignatov
Holm Eggemann
Elke Burger
Serban Dan Costa
Atanas Ignatov
Publikationsdatum
01.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-015-2060-9

Weitere Artikel der Ausgabe 2/2016

Journal of Cancer Research and Clinical Oncology 2/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.